Cryptotanshinone 隐丹参酮; Cryptotanshinon; Tanshinone c|cas:35825-57-1|西域试剂

Cryptotanshinone 隐丹参酮; Cryptotanshinon; Tanshinone c,98.69%

产品编号：Bellancom-N0174| CAS NO：35825-57-1| 分子式：C₁₉H₂₀O₃| 分子量：296.36

药理药效：具有抗氧化、抗衰老功能，对治疗冠心病、心绞痛、心肌损害有一定疗效。隐丹参酮具有抑菌作用，1mg/ml对金黄色葡萄球菌及绿脓杆菌均有抑制作用，对溶血性链球菌亦有一定抑制作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-N0174		￥350.00	杭州北京（现货）
Bellancom-N0174		￥950.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cryptotanshinone 隐丹参酮; Cryptotanshinon; Tanshinone c

产品介绍

Cryptotanshinone是从丹参的根中提取的天然化合物，具有抗肿瘤活性。 Cryptotanshinone抑制 STAT3 的 IC₅₀ 为4.6 μM。

生物活性

Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits STAT3 with an IC₅₀ of 4.6 μM.

体外研究

Cryptotanshinone significantly inhibits STAT3-dependent luciferase activity, the STAT3 Tyr705 phosphorylation and the dimerization of STAT3, compared to tanshinone IIA which exhibits no activity. Cryptotanshinone (7 μM) dramatically blocks STAT3 Tyr705 phosphorylation but not STAT3 Ser727 phosphorylation in DU145 cells, and significantly inhibits JAK2 phosphorylation with IC₅₀ of appr 5 μM without affecting the phosphorylation of upstream kinases c-Src and EGFR, suggesting the inhibition of STAT3 Tyr705 phosphorylation might due to a direct mechanism probably by binding to the SH2 domain of STAT3. Cryptotanshinone significantly inhibits the proliferation of DU145 prostate cancer cells harboring constitutively active STAT3 with GI₅₀ of 7 μM by blocking STAT3 activity, which leads to the down-regulation of cyclin D1, Bcl-xL, and survivin, subsequently the accumulation in the G0-G1 phase. Cryptotanshinone exhibits less growth inhibitory effect on PC3, LNCaP and MDA-MB-468 cells. Cryptotanshinone significantly attenuates the in vitro hormonal effects of DEX on ovaries, as indicated by a significant decrease in T and an increase in P levels in the culture medium. Cryptotanshinone significantly increases the levels of phosphorylated AKT2 and GSK3β in the DEX-treated ovaries. Cotreatment with imatinib and Cryptotanshinone shows a significant synergistic killing effect in both imatinib sensitive and resistant CML cell lines, as well as primary CML cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Cryptotanshinone reverses the ovarian IR and significantly increases 2-deoxy-D-[1,2-³H]-glucose uptake in all examined tissues from the DEX-treated mice. Cryptotanshinone significantly reduces the ovulation rate and plasma E2 and P levels. Cryptotanshinone administration significantly reduces the body weight and food intake of ob/ob mice (C57BL/6J-Lepob) and diet-induced obese (DIO) mice in a dose-dependent manner. Cryptotanshinone causes noticeably less fat in the adipose tissues, significant reductions of serum triglycerides and cholesterol levels, and 2.5- to 3-fold higher AMPK activity of the skeletal muscles than in the control mice. Oral administration of Cryptotanshinone at 600 mg/kg/day produces dramatic reductions in blood glucose levels of ob/ob mice (C57BL/6J-Lepob), db/db mice (C57BL/KsJ-Leprdb), and ZDF rats, which occur after 3 days and persist over the entirety of the monitoring period^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 2 mg/mL (6.75 mM; ultrasonic and warming and heat to 80°C)

H₂O : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3743 mL	16.8714 mL	33.7427 mL
5 mM	0.6749 mL	3.3743 mL	6.7485 mL
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 0.83 mg/mL (2.80 mM); Suspended solution; Need ultrasonic

此方案可获得 0.83 mg/mL (2.80 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.83 mg/mL (2.80 mM); Clear solution

此方案可获得 ≥ 0.83 mg/mL (2.80 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 0.83 mg/mL (2.80 mM); Clear solution

此方案可获得 ≥ 0.83 mg/mL (2.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Shin DS, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009 Jan 1;69(1):193-202. [Content Brief]

. Huang Y, et al. Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. Fertil Steril. 2014 Aug;102(2):589-596.e4. [Content Brief]

. Ge Y, et al. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells. Leuk Lymphoma. 2014 Jun 25:1-9. [Content Brief]

[4]. Kim EJ, et al. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol. 2007 Jul;72(1):62-72. Epub 2007 Apr 11. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

符号	GHS06, GHS09
信号词	Danger
危害声明	H301-H410
警示性声明	P273-P301 + P310-P501
个人防护装备	dust mask type N95 (US);Eyeshields;Gloves
危害码 (欧洲)	T,N
风险声明 (欧洲)	25-50/53
安全声明 (欧洲)	45-60-61
危险品运输编码	UN2811 - class 6.1 - PG 3 - EHS - Toxic solids, organic, n.o.s., HI: all
RTECS号	SF8282645
海关编码	2932999099

1. 物质的识别

产品名：	Cryptotanshinone
CAS号：	35825-57-1
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Cryptotanshinone
别名：	CTS
分子式：	C19H20O3
分子量：	296.36

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

上游产品 9
109664-02-0 2270-59-9 578-57-4 171979-69-4
33214-70-9 100-66-3 171979-70-7 171979-68-3
171979-67-2
下游产品 2
109664-02-0 568-72-9

43. [6.449] Chaogeng Lyu et al."A field trials-based study reveals the effects of chlormequat chloride on the quality of medicinal plant Salvia miltiorrhiza Bge. (Lamiaceae) in practical cultivation."INDUSTRIAL CROPS AND PRODUCTS.2023 Apr;194:116396

42. [6.208] Huan Zhao et al."Dihydrotanshinone I Inhibits the Lung Metastasis of Breast Cancer by Suppressing Neutrophil Extracellular Traps Formation."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2022 Jan;23(23):15180

41. [IF=1.496] Wenkai Wu et al."Cryptotanshinone From Salvia miltiorrhiza Inhibits the Growth of Tumors and Enhances the Efficacy of Chemotherapy in a Gastric Cancer Mouse Model."Natural Product Communications

40. [IF=5.988] Keke Guo et al."Cryptotanshinone protects skin cells from ultraviolet radiation-induced photoaging via its antioxidant effect and by reducing mitochondrial dysfunction and inhibiting apoptosis."Frontiers in Pharmacology.2022; 13: 1036013

39. [IF=0] Danni Wang et al."Identification of Q-Markers from Hedan Tablet by employing “spider-web” mode and taking compounds’ hepatotoxicity into account."Chinese Herbal Medicines.2022 Aug;:

38. [IF=6.317] Ping Huang et al."Optimization of smashing tissue and ultrasonic extraction of tanshinones and their neuroprotective effect on cerebral ischemia/reperfusion injury by inhibiting parthanatos."Food & Function.2022 Aug;:

37. [IF=6.627] Jiadong Hu et al."Identification of Abietane-Type Diterpenoids and Phenolic Acids Biosynthesis Genes in Salvia apiana Jepson Through Full-Length Transcriptomic and Metabolomic Profiling."Frontiers in Plant Science.2022; 13: 919025

36. [IF=7.376] Chengtao Sun et al."Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradation."Free Radical Bio Med. 2022 Feb;180:220

35. [IF=6.057] Qi Tong et al.Biosynthesis-based spatial metabolome of Salvia miltiorrhiza Bunge by combining metabolomics approaches with mass spectrometry-imaging.Talanta. 2021 Nov;:123045

34. [IF=2.971] Rubin Cheng et al."Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia."Pharm Biol. 2021;59(1):893-903

33. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950

32. [IF=3.411] Liu Hongyan et al."Effect Study of Continuous Monoculture on the Quality of Salvia miltiorrhiza Bge Roots."Biomed Res Int. 2020;2020:4284385

31. [IF=3.51] Li-Ying Peng et al."Salvia miltiorrhiza Restrains Reactive Oxygen Species-Associated Pulmonary Fibrosis via Targeting Nrf2-Nox4 Redox Balance."Am J Chinese Med. 2019 Aug;47(05):1113-1131

30. [IF=3.69] Qian Zhang et al."Qishen Granule alleviates endoplasmic reticulum stress-induced myocardial apoptosis through IRE-1-CRYAB pathway in myocardial ischemia."J Ethnopharmacol. 2020 Apr;252:112573

29. [IF=4.411] Xiaoping Wang et al."Cryptotanshinone Ameliorates Doxorubicin-Induced Cardiotoxicity by Targeting Akt-GSK-3β-mPTP Pathway In Vitro."Molecules. 2021 Jan;26(5):1460

28. [IF=4.411] Yuanyuan Li et al."Quantitative Determination and Validation of Four Ketones in Salvia miltiorrhiza Bunge Using Quantitative Proton Nuclear Magnetic Resonance Spectroscopy."Molecules. 2020 Jan;25(9):2043

27. [IF=5.34] Tao-Fang Cheng et al."Compound Dan Zhi tablet attenuates experimental ischemic stroke via inhibiting platelet activation and thrombus formation."Phytomedicine. 2020 Dec;79:153330

26. [IF=6.475] Shi Qiu et al."Selection of appropriate post-harvest processing methods based on the metabolomics analysis of Salvia miltiorrhiza Bunge."Food Res Int. 2021 Jun;144:110366

25. [IF=7.514] Tong Wang et al."A hydrophobic deep eutectic solvents-based integrated method for efficient and green extraction and recovery of natural products from Rosmarinus officinalis leaves, Ginkgo biloba leaves and Salvia miltiorrhiza roots."Food Chem. 2021 Nov;3

24. [IF=3.361] Taofang Cheng et al."Hybrid multidimensional data acquisition and data processing strategy for comprehensive characterization of known, unknown and isomeric compounds from the compound Dan Zhi Tablet by UPLC-TWIMS-QTOFMS."Rsc Adv. 2019 Mar;9(16):8714-8727

23. [IF=3.414] Yu-xiang Fei et al."Salvia miltiorrhiza Bunge (Danshen) extract attenuates permanent cerebral ischemia through inhibiting platelet activation in rats."J Ethnopharmacol. 2017 Jul;207:57

22. [IF=3.935] Nan Mi et al."Metabolite profiling of traditional Chinese medicine formula Dan Zhi Tablet: An integrated strategy based on UPLC-QTOF/MS combined with multivariate statistical analysis."J Pharmaceut Biomed. 2019 Feb;164:70

21. [IF=5.64] Wu Dousheng et al."Oleanolic Acid Induces the Type III Secretion System of Ralstonia solanacearum."Front Microbiol. 2015 Dec;0:1466

20. [IF=7.514] Tiehua Zhang et al."In vitro and in silico perspectives on estrogenicity of tanshinones from Salvia miltiorrhiza."Food Chem. 2019 Jan;270:281

19. Xia, Yanqiu, et al. "Cryptotanshinone reverses reproductive disturbances in rats with dehydroepiandrosterone-induced polycystic ovary syndrome." American journal of translational research 9.5 (2017): 2447.

18. 李晓婷,决利利,郝海军,王世广.隐丹参酮纳米混悬剂的制备及其抗肿瘤活性[J].中成药,2021,43(01):6-10.

17. 马丽娟,王锡恩,刘培,陈蜜,张静,彭敏.隐丹参酮调控Wnt/β-catenin信号通路对胃癌细胞抑制作用的研究[J].新中医,2020,52(21):1-5.

16. 陈天朝,耿梦丽,马彦江,李沁,姚超,程思卿,王娇.丹参不同炮制品饮片与标准汤剂的物性参数及化学成分相关性[J].中成药,2021,43(03):824-829

15. 赵志国, 段文娟, 张晓梦,等. HPLC-DAD-ESI-TOF/MS鉴别和测定前列欣胶囊中多种成分及其多指标定量指纹图谱研究[J]. 药物分析杂志, 2017, 037(010):1810-1816.

14. 李清清张继芬. 冠心宁中14种成分的含量测定[J]. 苏盐科技 2019 046(006):33-35.

13. 王芸, 陈军峰, 张磊,等. 基于"有效成分-性状"的关联分析评价丹参品质的研究[J]. 世界科学技术:中医药现代化, 2019(5):835-843.

12. 崔伟亮. 丹参酒炙前后HPLC指纹图谱色谱峰归属比较[J]. 辽宁中医杂志, v.46;No.507(08):1707-1709.

11. 敏敏赵志国刘伟等. HPLC-DAD法同时测定三种来源丹参饮片中水溶性和脂溶性成分[J]. 山东科学 2019(6).

10. 石蔚华赵筱萍陈晓玲.三叶糖脂清DPP-4抑制成分筛选及其调控JNK/AKT信号通路改善胰岛素抵抗的机制研究[J].浙江中医药大学学报 2019 43(01):7-13.

9. 闫妍石磊史宁郭宏举耿帅温彬宇.UPLC-Q-TOF-MS同时测定天王补心片中丹参的主要成分[J].解放军药学学报 2018 34(01):55-57.

8. 孙锦林力彭勍等. 不同浓度乙醇提取丹参中12种成分比较研究[J]. 中国中医药信息杂志 2019(9).

7. 郝海军, 屈战果, 范明松. 隐丹参酮纳米结构脂质载体的制备及药动学研究[J]. 中成药, 2020, 042(004):831-835.

6. 邓凤春, 于占江, 杨钰,等. 隐丹参酮对人胃癌细胞SGC-7901凋亡的影响及其机制[J]. 北京中医药大学学报, 2015.

5. 邓凤春, 杨钰, 赵红晔,等. 隐丹参酮抑制人胃癌SGC-7901细胞增殖的实验研究[J]. 中外医疗, 2014(35):49-50.

4. 彭国文,柳超,時晓静,郝海军.隐丹参酮固体脂质纳米粒的制备及药动学研究[J].中药材,2019,42(03):626-629.

3. 何家杰,李敏,唐国富,李厚泽,綦晓龙.异隐丹参酮对胃癌细胞增殖、周期和凋亡的影响[J].临床肿瘤学杂志,2019,24(02):129-132.

2. 张玉, 戚莹雪, 王蕾,等. 山东丹参脂溶性成分的地域分布特点研究[J]. 中药材, 2018, 041(011):2522-2526.

1. 张芮乾,吴晓毅,胡添源,宋雅迪,高伟,黄璐琦.基于丹参酮类化合物生源途径的丹参质量标志物研究思路探讨[J].中国中药杂志,2020,45(13):3098-3103.

Cryptotanshinone 隐丹参酮; Cryptotanshinon; Tanshinone c,98.69%

Cryptotanshinone 隐丹参酮; Cryptotanshinon; Tanshinone c

化学品安全说明书(MSDS)

质检证书(COA)

1. 物质的识别

2. 合成/成分数据

3. 急救措施

4. 消防措施

5. 泄漏应急处理

6. 处理和储存

7. 接触控制和个人防护

8. 稳定性和反应活性

9. 毒性资料

10. 生态资料

11. 废弃处置

12. 运输信息

13. 法规信息

14. 其他信息

在线咨询